Literature DB >> 31241553

Cardiac Allograft Vasculopathy: The Enduring Enemy of Cardiac Transplantation.

Andriana P Nikolova1, Jon A Kobashigawa1.   

Abstract

Cardiac allograft vasculopathy remains a major limiting factor in the long-term survival of the heart transplant recipient. Our understanding of its pathogenesis is continuously evolving as advances in imaging modalities have allowed a direct window into the natural history of the disease. Innovation in diagnostic modalities has spurred the proliferation of prognostic tools and biomarkers. And in parallel, pharmacological advances have emerged that have helped ameliorate the disease's progressive course.

Entities:  

Mesh:

Year:  2019        PMID: 31241553     DOI: 10.1097/TP.0000000000002704

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Center-level Utilization of Hepatitis C Virus-positive Donors for Orthotopic Heart Transplantation.

Authors:  Lauren V Huckaby; Laura M Seese; Robert Handzel; Yisi Wang; Gavin Hickey; Arman Kilic
Journal:  Transplantation       Date:  2021-12-01       Impact factor: 4.939

2.  The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis.

Authors:  Dominika Klimczak-Tomaniak; Stefan Roest; Jasper J Brugts; Kadir Caliskan; Isabella Kardys; Felix Zijlstra; Alina A Constantinescu; Jolanda J C Voermans; Jeroen J A van Kampen; Olivier C Manintveld
Journal:  Transplantation       Date:  2020-07       Impact factor: 5.385

3.  Everolimus-eluting stents versus sirolimus-eluting stents in patients with cardiac allograft vasculopathy.

Authors:  Michał Hawranek; Łukasz Pyka; Bożena Szyguła-Jurkiewicz; Piotr Desperak; Wioletta Szczurek; Andrzej Lekston; Michał Zembala; Szymon Pawlak; Mariusz Gąsior; Piotr Przybyłowski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2021-12-16       Impact factor: 1.426

4.  Lack of Usefulness of Donor-Derived Cell-Free DNA as a Biomarker for Cardiac Allograft Vasculopathy: A Prospective Study.

Authors:  Marta Jiménez-Blanco Bravo; Laura Pérez-Gómez; Francisco J Hernández-Pérez; Carlos Arellano-Serrano; Mario Torres-Sanabria; Manuel Gómez-Bueno; Juan F Oteo-Domínguez; Susana Mingo-Santos; Javier Segovia-Cubero
Journal:  Front Cardiovasc Med       Date:  2022-04-06

Review 5.  Cardiac allograft vasculopathy: current review and future research directions.

Authors:  Jordan S Pober; Sharon Chih; Jon Kobashigawa; Joren C Madsen; George Tellides
Journal:  Cardiovasc Res       Date:  2021-11-22       Impact factor: 10.787

6.  Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation.

Authors:  Eilon Ram; Jacob Lavee; Alexander Tenenbaum; Robert Klempfner; Enrique Z Fisman; Elad Maor; Tal Ovdat; Sergei Amunts; Leonid Sternik; Yael Peled
Journal:  Cardiovasc Diabetol       Date:  2019-09-16       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.